Share
Services
Fresenius Annual Report 2023 (IFRS)
Participations in affiliated and associated companies 2023
The Supervisory Board of Fresenius Management SE extended Sara Hennicken's mandate as Chief Financial Officer (CFO) ahead of time until 2027. Originally, it was set to run until 2025. The company thus ensures continuity on the Management Board in order to further advance the #FutureFresenius strategy.
Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius: “Sara Hennicken has successfully helped drive #FutureFresenius. In doing so, she has significantly improved the transparency in the finance function – this is an important prerequisite for managing the company and its businesses. We are very much looking forward to continuing our collaboration with her.”
Sara Hennicken (43) has been Chief Financial Officer of Fresenius since September 1, 2022. She joined the company in 2019 as Senior Vice President Global Treasury & Corporate Finance for Fresenius and Fresenius Medical Care. Prior to this, she worked in investment banking for 14 years, including nine years at Deutsche Bank. Most recently, Hennicken was Managing Director and Senior Client Executive in the Corporate Finance Coverage division. From 2005 to 2010, she worked for Citigroup in Frankfurt and London. Hennicken studied economics and business administration in Germany and the USA.
With its #FutureFresenius strategy, Fresenius is focusing on its operating companies Fresenius Kabi and Fresenius Helios. Both business segments occupy leading positions in attractive growth markets. With (Bio)Pharma, MedTech and Care Provision, they cover three central growth platforms in the therapy sector. To further increase the company's performance, the Management Board has also introduced a new, streamlined financial management system as a component of #FutureFresenius. Ambitious EBIT margin bands have been defined for the business segments as part of the Fresenius Financial Framework, which serve as benchmarks for management.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.
Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius Kabi announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Tyenne® (tocilizumab-aazg), its tocilizumab biosimilar referencing Actemra®* (tocilizumab). Tyenne® becomes the first tocilizumab biosimilar with both IV and subcutaneous formulations approved by the FDA. In accordance with its patent settlement agreement with Genentech, Fresenius Kabi has a license to market its tocilizumab product in the U.S. commencing on the license dates, which are confidential.
Tyenne® is Fresenius Kabi’s third approved U.S. biosimilar and another landmark in the company’s growth strategy towards #FutureFresenius. Recent launches were Tyenne® to treat inflammatory and autoimmune diseases in the EU as well as Idacio® and Stimufend®, expanding treatment options for autoimmune diseases and cancer in the U.S.
* Actemra® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.
Fresenius Kabi announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Tyenne® (tocilizumab-aazg), its tocilizumab biosimilar referencing Actemra®* (tocilizumab). Tyenne® becomes the first tocilizumab biosimilar with both IV and subcutaneous formulations approved by the FDA. In accordance with its patent settlement agreement with Genentech, Fresenius Kabi has a license to market its tocilizumab product in the U.S. commencing on the license dates, which are confidential.
Tyenne® is Fresenius Kabi’s third approved U.S. biosimilar and another landmark in the company’s growth strategy towards #FutureFresenius. Recent launches were Tyenne® to treat inflammatory and autoimmune diseases in the EU as well as Idacio® and Stimufend®, expanding treatment options for autoimmune diseases and cancer in the U.S.
* Actemra® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.
Colon cancer is the second most common type of cancer in men and women. The risk of developing colon cancer, however, can be reduced with regular screenings. The gold standard diagnostic tool here is a colonoscopy, which is recommended in Germany for men from the age of 50 and women from the age of 55. It is recommended that people with a family history of colon cancer undergo this examination from the age of 40.
The colonoscopy ideally needs to be able to detect all of the precancerous stages. Such a precancerous stage refers to a change in the tissue that is not yet malignant but has the potential to develop into cancer. Some types of polyps – growths in the mucous membrane of the intestine that are often left to grow unnoticed over many years – are precancerous stages. With one type of polyp in particular, namely adenomas, there is a high risk that they will develop into colon cancer, and the larger the adenoma, the more likely the affected person is to develop cancer. Besides, there is also an extremely wide range of different types of polyps.
During a screening colonoscopy, the teams of medics need to ensure that all precancerous stages are reliably detected and removed. This is the only way to significantly reduce the risk of a malignant tumor developing. But the variety of different types means that it is sometimes difficult to reliably diagnose polyps. Sessile polyps or those that occur behind folds can be overlooked during even a thorough colonoscopy. For a long time, special endoscopic procedures have been used for this, with the aim of minimizing the rate of overlooked polyps.
But the latest development in colonoscopies is the use of artificial intelligence, whereby a computer algorithm detects polyps in the intestinal mucosa during an endoscopy. As soon as the computer has made a find and detected a polyp, it sets off an optical and acoustic signal, and the examining physician is notified of the finding. Various different artificial intelligence systems have already been approved for use in colonoscopies.
The state-of-the-art Colon Cancer Center in the Helios Dr. Horst Schmidt Hospital has been routinely using artificial intelligence in the diagnosis of intestinal polyps for a long time.
“The use of AI in preventive colonoscopies significantly increases the rate of polyp detection. This allows us to offer the patient a much more precise screening without additional risk for our patients”, says Prof. Dr. Ingmar Mederacke, Director of the Clinic for Gastroenterology, Hepatology and Endocrinology.
The reliability of these systems is incredibly high. Studies have shown that artificial intelligence leads to a significantly increased detection rate when it comes to polyps. And the good news is that doctors aren’t being replaced, but are instead able to use the computer to support their diagnostics. AI provides additional information that would be overlooked by the human eye.
Fresenius Kabi announced today it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms of cancer. The introduction adds another life-saving treatment to Fresenius Kabi’s broad oncology portfolio that offers lower-cost options for treating a wide range of cancers.
For more information, please see the website of Fresenius Kabi.
Fresenius Kabi announced today it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms of cancer. The introduction adds another life-saving treatment to Fresenius Kabi’s broad oncology portfolio that offers lower-cost options for treating a wide range of cancers.
For more information, please see the website of Fresenius Kabi.
